Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on ADC Therapeutics. The associated price target remains the same with $7.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Robert Burns has given his Buy rating due to a combination of factors including ADC Therapeutics’ financial performance and upcoming clinical data catalysts. The company reported a narrower net loss for 3Q25 than previously estimated, indicating better financial management. Additionally, ADC Therapeutics has a strong cash position that is expected to support operations into the second half of 2026, providing a stable financial runway.
Furthermore, the anticipated data updates from the LOTIS-7 and LOTIS-5 trials are significant catalysts that could enhance the company’s market position. The LOTIS-7 trial is expected to provide additional data by the end of 2025, while the LOTIS-5 trial results are anticipated in the first half of 2026. These trials could potentially lead to confirmatory FDA approval, which would be a major milestone for the company. The valuation approach used by Burns, which includes a discounted cash flow model, supports a positive outlook with a price target of $7 per share, despite inherent risks such as approval delays and market uptake challenges.
In another report released on November 11, Guggenheim also maintained a Buy rating on the stock with a $10.00 price target.